Ilika plc

Ilika plc

ILIKF
Ilika plcUS flagOther OTC
0.48
USD
-0.01
- -
87.16MMarket Cap
Ilika plc
ILIKF
(Other OTC)

Recent

price

0.48

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
8.65
0.04
0.05
0.02
0.02
0.02
0.01
0.01
0.03
0.03
0.03
0.02
- -
- -
- -
- -
Revenue per Share
-25.54
-0.08
-0.07
-0.07
-0.05
-0.04
-0.05
-0.05
-0.04
-0.02
-0.03
-0.03
-0.05
-0.05
-0.03
-0.04
Basic EPS, GAAP
-14.62
-0.06
-0.05
-0.08
-0.04
-0.04
-0.05
-0.05
-0.03
-0.03
-0.03
-0.04
-0.07
-0.05
-0.03
-0.04
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-31.19
-0.16
-0.22
-0.25
-0.28
-0.26
-0.31
-0.32
-0.32
-0.29
-0.29
-0.24
-0.26
-0.29
-0.32
-0.35
Book Value per Share
21.12
0.12
0.17
0.07
0.15
0.1
0.05
0.08
0.05
0.06
0.16
0.09
0.19
0.14
0.1
0.08
Tangible Book Value per Share
- -
39
39
48
53
67
67
74
80
96
105
140
153
159
159
159
Basic Weighted Avg Shares
1
2
2
1
1
1
1
1
2
3
3
2
- -
- -
- -
- -
Sales/Revenue/Turnover
-308.01
-206.03
-128.68
-354.69
-295.83
-282.08
-636.98
-374.46
-159.31
-104.01
-117.75
-170.29
-1,636.59
-26,619.82
-31,043.78
-10,286.94
Operating Margin (%)
1
1
1
1
1
- -
- -
- -
- -
- -
1
1
1
2
2
2
Depreciation Expense
-3
-3
-3
-3
-3
-3
-3
-4
-3
-2
-3
-4
-7
-7
-5
-6
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-295.19
-197.28
-146.41
-346.13
-266.52
-246.96
-572.84
-336.95
-141.25
-89.61
-108.7
-156.36
-1,436.91
-21,585.8
-23,947.26
-8,030.2
Profit Margin (%)
1
3
5
2
7
6
3
6
3
4
16
11
24
18
13
9
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
- -
- -
- -
LT Debt
3
5
7
3
8
7
3
6
4
6
17
14
31
25
20
17
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
29.35%
9.89%
-15.62%
Free Cash Flow
16.83%
26.89%
52.29%
Net Income, GAAP
13.27%
21.45%
22.62%
Sales/Revenue/Turnover
19.33%
6.67%
265.67%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.03
2025
- -
- -
- -
- -
-0.04
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Ilika plc develops and manufactures solid-state batteries for MedTech, Industrial IoT, electric vehicles, and consumer electronics applications; its core products include the Stereax family of miniature batteries, such as the M300 model for medical implants and wireless sensors with low leakage, long cycle life, and mm-scale form factors; and the Goliath large-format batteries offering high energy density, fast charging, safety, and extended range for EVs and cordless appliances. Founded in 2004 as a spin-out from the University of Southampton and headquartered in Romsey, UK, the company operates primarily in the UK with global partnerships and targets OEMs, Tier 1 suppliers, and medical device manufacturers across Europe, North America, and Asia. Recent developments include a 2023 ten-year manufacturing license with Cirtec Medical in Massachusetts for Stereax production and commercialization support for 21 customers in orthopedics, neurostimulation, and smart lenses; a bilateral technology collaboration and heads of terms with Agratas for Goliath scale-up via the SiSTEM project adding 1.5 MWh assembly capacity; post-period fundraises of £4.2 million in 2025 and £3.5 million earlier to advance both product lines; and £1.25 million grant funding from the DRIVE35 programme commencing August 2025 with HSSMI for Goliath manufacturing.

Company News

APIChat
  • Eli Lilly weight loss drug data supports long-term obesity market position, says UBS

  • Goldman Sachs CEO says AI job fears ‘overblown’

  • Ilika advances Goliath commercialisation strategy - ICYMI

  • Ilika advances Goliath commercialisation strategy - ICYMI

  • Palo Alto Networks customers show confidence in AI security strategy at Ignite On Tour event, Jefferies says

  • Workday execution risk flagged by Jefferies ahead of quarterly earnings

  • Nvidia beats, guides higher, and Wall Street still wants more

  • Ilika's broadening commercial pipeline supports broker's conviction in solid-state battery play

  • Ilika's broadening commercial pipeline supports broker's conviction in solid-state battery play

  • Ilika begins generating commercial revenue from solid-state batteries

  • Percheron Therapeutics raises $2.2 million as HMBD-002 phase II preparations advance

  • FTSE 100 Live: Stocks sink as oil pushes above $117, GSK and Haleon fall on results

  • Palantir Technologies Q1 expectations buoyed by commercial acceleration, government contracts

  • Nasdaq falls back after mixed earnings, Fed holds but signals dissent

  • FTSE 100 Live: London blue-chips led lower by miners, builders and airlines

  • Ilika Goliath batteries in Brompton next-gen e-bikes collaboration - ICYMI

  • Ilika Goliath batteries in Brompton next-gen e-bikes collaboration - ICYMI

  • Ilika has cracked problems that have beaten BYD, Toyota and Samsung. So why is nobody paying attention?

  • Ilika has cracked problems that have beaten BYD, Toyota and Samsung. So why is nobody paying attention?

  • Ralph Lauren price target boosted on stronger brand positioning among luxury peers